Back

Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?

European Heart Journal

18 January 2019
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE Myocardial Disease Pharmacology and Pharmacotherapy

Abstract

Abstract

Contributors

Rodney H Falk
Rodney H Falk

Author

You may be interested in
thumbnail
Congress Presentation
Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy
29 June 2021
thumbnail
Congress Presentation
Evolving the understanding of TTR's role in health and disease​
31 August 2025
thumbnail
Congress Presentation
Tafamidis in patients with amyloid cardiomyopathy: a systematic review and meta-analysis of 14 studies.
1 September 2025
thumbnail
Congress Session
ACT FAST for ATTR-CM: early clues in heart failure to raise clinical suspicion
17 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources